{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T05:21:08Z","timestamp":1769059268018,"version":"3.49.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurocirug\u00eda"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.neucir.2015.04.001","type":"journal-article","created":{"date-parts":[[2015,7,18]],"date-time":"2015-07-18T08:23:57Z","timestamp":1437207837000},"page":"276-283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Importancia de la mutaci\u00f3n de la isocitrato deshidrogenasa tipo I como factor pron\u00f3stico en pacientes con glioblastomas y revisi\u00f3n de la literatura"],"prefix":"10.1016","volume":"26","author":[{"given":"Cristian","family":"de Quintana-Schmidt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jes\u00fas","family":"Alvarez-Holzapfel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep","family":"Nomdedeu-Guinot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Bague-Rosell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oscar","family":"Gallego-Rubio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Leidinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Salgado-Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Molet-Teixid\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neucir.2015.04.001_bib0205","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00401-005-0991-y","article-title":"Epidemiology and etiology of gliomas","volume":"109","author":"Ohgaki","year":"2005","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neucir.2015.04.001_bib0210","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3109\/02688697.2012.752432","article-title":"Diagnostic and prognostic markers in gliomas. An update","volume":"27","author":"Ma","year":"2013","journal-title":"Br J Neurosurg."},{"key":"10.1016\/j.neucir.2015.04.001_bib0215","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1600-0404.2010.01350.x","article-title":"Overall survival, prognostic factors, and repeated surgery in a consecutive series of 516 patients with glioblastoma multiforme","volume":"122","author":"Helseth","year":"2010","journal-title":"Acta Neurol Scand."},{"key":"10.1016\/j.neucir.2015.04.001_bib0220","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3171\/jns.2001.95.2.0190","article-title":"A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival","volume":"95","author":"Lacroix","year":"2001","journal-title":"J Neurosurg."},{"key":"10.1016\/j.neucir.2015.04.001_bib0225","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00401-007-0243-4","article-title":"The 2007 WHO classification of tumours of the central nervous system","volume":"114","author":"Louis","year":"2007","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neucir.2015.04.001_bib0230","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s10014-012-0113-1","article-title":"Histopathological malignant progression of grade II and III gliomas correlated with IDH1\/2 mutation status","volume":"29","author":"Ohno","year":"2012","journal-title":"Brain Tumor Pathol."},{"key":"10.1016\/j.neucir.2015.04.001_bib0235","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1200\/JCO.2010.33.8715","article-title":"Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin","volume":"29","author":"Lai","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.neucir.2015.04.001_bib0240","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s10014-012-0090-4","article-title":"Molecular pathogenesis of IDH mutations in gliomas","volume":"29","author":"Ichimura","year":"2012","journal-title":"Brain Tumor Pathol."},{"issue":"Suppl 4","key":"10.1016\/j.neucir.2015.04.001_bib0245","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/neuonc\/nos206","article-title":"Personalized care in neuro-oncology coming of age: why we need MGMT and 1p\/19q testing for malignant glioma patients in clinical practice","volume":"14","author":"Weller","year":"2012","journal-title":"Neuro-Oncology."},{"key":"10.1016\/j.neucir.2015.04.001_bib0250","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/neuonc\/not027","article-title":"1p\/19q codeletion and IDH1\/2 mutation identified a subtype of anaplastic oligoastrocytomas with prognosis as favorable as anaplastic oligodendrogliomas","volume":"15","author":"Jiang","year":"2013","journal-title":"Neuro-Oncology."},{"key":"10.1016\/j.neucir.2015.04.001_bib0255","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.canlet.2012.12.024","article-title":"Understanding high grade glioma: molecular mechanism, therapy and comprehensive management","volume":"331","author":"Wang","year":"2013","journal-title":"Cancer Letters."},{"key":"10.1016\/j.neucir.2015.04.001_bib0260","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00401-014-1370-3","article-title":"ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an integrated diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma","volume":"129","author":"Reuss","year":"2015","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neucir.2015.04.001_bib0265","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.18632\/oncotarget.1838","article-title":"ATRX mRNA expression combined with IDH1\/2 mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors: evidence from the whole transcriptome sequencing of 169 samples samples","volume":"5","author":"Cai","year":"2014","journal-title":"Oncotarget."},{"key":"10.1016\/j.neucir.2015.04.001_bib0270","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1093\/neuonc\/not015","article-title":"Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing","volume":"15","author":"Agarwal","year":"2013","journal-title":"Neuro-Oncology."},{"key":"10.1016\/j.neucir.2015.04.001_bib0275","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1126\/science.1164382","article-title":"An integrated genomic analysis of human glioblastoma multiforme","volume":"321","author":"Parsons","year":"2008","journal-title":"Science."},{"key":"10.1016\/j.neucir.2015.04.001_bib0280","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1470-2045(10)70053-X","article-title":"Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?","volume":"12","author":"Kloosterhof","year":"2010","journal-title":"Lancet Oncology."},{"key":"10.1016\/j.neucir.2015.04.001_bib0285","doi-asserted-by":"crossref","first-page":"e68782","DOI":"10.1371\/journal.pone.0068782","article-title":"IDH1\/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis","volume":"8","author":"Zou","year":"2013","journal-title":"PLoS One."},{"key":"10.1016\/j.neucir.2015.04.001_bib0290","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJMoa0808710","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"360","author":"Yan","year":"2009","journal-title":"N Engl J Med."},{"key":"10.1016\/j.neucir.2015.04.001_bib0295","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00401-008-0455-2","article-title":"Analysis of the IDH1 codon 132 mutation in brain tumors","volume":"116","author":"Balss","year":"2008","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neucir.2015.04.001_bib0300","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/neuonc\/nos317","article-title":"IDH\/MGMT driven molecular classification of low-grade glioma is a strong predictor for long-term survival","volume":"15","author":"Leu","year":"2013","journal-title":"Neuro-Oncology."},{"key":"10.1016\/j.neucir.2015.04.001_bib0305","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s10014-013-0140-6","article-title":"Secondary glioblastomas with IDH1\/2 mutations have longer glioma history from preceding lower-grade gliomas","volume":"30","author":"Ohno","year":"2013","journal-title":"Brain Tumor Pathol."},{"key":"10.1016\/j.neucir.2015.04.001_bib0310","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11060-012-0831-6","article-title":"1P19Q loss but not IDH1 mutations influences WHO grade II gliomas spontaneous growth","volume":"108","author":"Goz\u00e9","year":"2012","journal-title":"J Neurooncol."},{"key":"10.1016\/j.neucir.2015.04.001_bib0315","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.2353\/ajpath.2009.080958","article-title":"IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas","volume":"174","author":"Watanabe","year":"2010","journal-title":"Am J Pathol."},{"key":"10.1016\/j.neucir.2015.04.001_bib0320","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/jnci\/djq497","article-title":"DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma","volume":"103","author":"Christensen","year":"2011","journal-title":"J Natl Cancer Inst."},{"key":"10.1016\/j.neucir.2015.04.001_bib0325","first-page":"84","article-title":"Methylation pro- filing identifies 2 groups of gliomas according to their tumorigenesis","volume":"13","author":"Laffaire","year":"2011","journal-title":"Neurooncology."},{"key":"10.1016\/j.neucir.2015.04.001_bib0330","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ccr.2010.03.017","article-title":"Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma","volume":"17","author":"Noushmehr","year":"2010","journal-title":"Cancer Cell."},{"key":"10.1016\/j.neucir.2015.04.001_bib0335","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.clineuro.2012.04.005","article-title":"The influence of surgery on recurrence pattern of glioblastoma","volume":"115","author":"De Bonis","year":"2013","journal-title":"Clin Neurol Neurosurg."},{"key":"10.1016\/j.neucir.2015.04.001_bib0340","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1227\/01.neu.0000317304.31579.17","article-title":"Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias","volume":"62","author":"Stummer","year":"2008","journal-title":"Neurosurgery."},{"key":"10.1016\/j.neucir.2015.04.001_bib0345","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s11060-012-0844-1","article-title":"IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas","volume":"108","author":"Juratli","year":"2012","journal-title":"J Neurooncol."},{"key":"10.1016\/j.neucir.2015.04.001_bib0350","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1212\/WNL.0b013e3181f96282","article-title":"IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas","volume":"75","author":"Houillier","year":"2010","journal-title":"Neurology."},{"key":"10.1016\/j.neucir.2015.04.001_bib0355","doi-asserted-by":"crossref","first-page":"6002","DOI":"10.1158\/1078-0432.CCR-09-0715","article-title":"Mutations as molecular signature and predictive factor of secondary glioblastomas","volume":"15","author":"Nobusawa","year":"2009","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.neucir.2015.04.001_bib0360","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/neuonc\/not006","article-title":"Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas","volume":"15","author":"Juratli","year":"2013","journal-title":"Neuro-Oncology."},{"key":"10.1016\/j.neucir.2015.04.001_bib0365","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s11910-013-0345-4","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"13","author":"Cohen","year":"2013","journal-title":"Curr Neurol Neurosci Rep."},{"key":"10.1016\/j.neucir.2015.04.001_bib0370","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1212\/WNL.0b013e31826e9b0a","article-title":"Detection of IDH1 mutation in the plasma of patients with glioma","volume":"79","author":"Boisselier","year":"2012","journal-title":"Neurology."},{"key":"10.1016\/j.neucir.2015.04.001_bib0375","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1158\/1078-0432.CCR-11-2977","article-title":"IDH Mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma","volume":"18","author":"Gorovets","year":"2012","journal-title":"Clinical Cancer Research."},{"key":"10.1016\/j.neucir.2015.04.001_bib0380","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/ijc.26425","article-title":"2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1\/2 mutation status or tumor size","volume":"131","author":"Capper","year":"2012","journal-title":"Int J Cancer."},{"key":"10.1016\/j.neucir.2015.04.001_bib0385","doi-asserted-by":"crossref","first-page":"116ra4","DOI":"10.1126\/scitranslmed.3002693","article-title":"Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy","volume":"4","author":"Andronesi","year":"2012","journal-title":"Sci Transl Med."},{"key":"10.1016\/j.neucir.2015.04.001_bib0390","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1172\/JCI67229","article-title":"Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate","volume":"123","author":"Andronesi","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.neucir.2015.04.001_bib0395","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nm.2682","article-title":"2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas","volume":"18","author":"Choi","year":"2012","journal-title":"Nat Med."},{"key":"10.1016\/j.neucir.2015.04.001_bib0400","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ijrobp.2010.06.012","article-title":"Validation and simplification of the radiation therapy oncology group recursive partitioning analysis classification for glioblastoma","volume":"81","author":"Li","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys."}],"container-title":["Neurocirug\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130147315000494?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130147315000494?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T20:56:15Z","timestamp":1537476975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130147315000494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S1130147315000494"],"URL":"https:\/\/doi.org\/10.1016\/j.neucir.2015.04.001","relation":{},"ISSN":["1130-1473"],"issn-type":[{"value":"1130-1473","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Importancia de la mutaci\u00f3n de la isocitrato deshidrogenasa tipo I como factor pron\u00f3stico en pacientes con glioblastomas y revisi\u00f3n de la literatura","name":"articletitle","label":"Article Title"},{"value":"Neurocirug\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neucir.2015.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Sociedad Espa\u00f1ola de Neurocirug\u00eda. Published by Elsevier Espa\u00f1a, S.L. All rights reserved.","name":"copyright","label":"Copyright"}]}}